Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.
Paz-Ares L, Forster M, Boni V, Szyldergemajn S, Corral J, Turnbull S, Cubillo A, Teruel CF, Calderero IL, Siguero M, Bohan P, Calvo E. Paz-Ares L, et al. Invest New Drugs. 2017 Apr;35(2):198-206. doi: 10.1007/s10637-016-0410-3. Epub 2016 Nov 21. Invest New Drugs. 2017. PMID: 27873130 Free article. Clinical Trial.
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
Forster M, Hackshaw A, De Pas T, Cobo M, Garrido P, Summers Y, Dingemans AC, Flynn M, Schnell D, von Wangenheim U, Loembé AB, Kaiser R, Lee SM. Forster M, et al. Lung Cancer. 2018 Jun;120:27-33. doi: 10.1016/j.lungcan.2018.03.007. Epub 2018 Mar 9. Lung Cancer. 2018. PMID: 29748012 Free article. Clinical Trial.
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours.
Arkenau HT, Italiano A, Mak G, Toulmonde M, Baird RD, Garcia-Corbacho J, Plummer R, Flynn M, Forster M, Wilson RH, Tosi D, Adenis A, Donaldson K, Posner J, Kawabata I, Arimura A, Deva S, Spicer J. Arkenau HT, et al. Eur J Cancer. 2018 Nov;103:17-23. doi: 10.1016/j.ejca.2018.07.134. Epub 2018 Sep 6. Eur J Cancer. 2018. PMID: 30196106 Free article. Clinical Trial.
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.
Kristeleit R, Evans J, Molife LR, Tunariu N, Shaw H, Slater S, Haris NRM, Brown NF, Forster MD, Diamantis N, Rulach R, Greystoke A, Asghar U, Rata M, Anderson S, Bachmann F, Hannah A, Kaindl T, Lane HA, Larger PJ, Schmitt-Hoffmann A, Engelhardt M, Tzankov A, Plummer R, Lopez J. Kristeleit R, et al. Among authors: forster md. Br J Cancer. 2020 Oct;123(9):1360-1369. doi: 10.1038/s41416-020-1010-8. Epub 2020 Aug 3. Br J Cancer. 2020. PMID: 32741975 Free PMC article. Clinical Trial.
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
Kristeleit R, Moreno V, Boni V, Guerra EM, Kahatt C, Romero I, Calvo E, Basté N, López-Vilariño JA, Siguero M, Alfaro V, Zeaiter A, Forster M. Kristeleit R, et al. Int J Gynecol Cancer. 2021 Nov;31(11):1428-1436. doi: 10.1136/ijgc-2021-002881. Epub 2021 Oct 5. Int J Gynecol Cancer. 2021. PMID: 34610971 Free PMC article. Clinical Trial.
142 results